Early-stage financing of pharmaceuticals and biotechnology has nose-dived in recent years, sparking concern that Britain could be wasting its opportunity to lead the world in medical science. Critics are quick to blame venture capitalists for refusing to invest on grounds of high risk and diminished returns – but is this justified?
Fund invests equity tickets in the range of €200m-1bn in North American and European companies
Freight service makes its second bolt-on of 2020, having acquired Nova Traffic in May
Clinics will operate under MVZ Meine Gynäkologie Lüdenscheid, a Meine Radiologie Holding subsidiary
GP is deploying capital from its second fund, which closed in 2017 on €600m